Tanvex BioPharma Profit Margin

The latest profit margin for 6541.TW is -222.84% as of June 2026. That compares with -1263.84% in the prior-year period — up 82.4% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Tanvex BioPharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, 6541.TW's profit margin moved from -1263.84% to -222.84% — a 82.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Tanvex BioPharma's valuation or profitability profile.

Against Healthcare companies, 6541.TW currently prints -222.84% for profit margin, while the sector average sits near 9.48%. That is roughly 2450.4% below the sector mean. Large gaps often invite a closer look at Tanvex BioPharma's growth, margins, and balance sheet.

Profit Margin shows how effectively Tanvex BioPharma converts resources into returns. At -222.84%, 6541.TW may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1263.84% in the prior-year period — up 82.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 6541.TW's profit margin (-222.84%), review year-over-year change from -1263.84%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.